Matches in Wikidata for { <http://www.wikidata.org/entity/Q99576761> ?p ?o ?g. }
Showing items 1 to 77 of
77
with 100 items per page.
- Q99576761 description "artículu científicu espublizáu en setiembre de 2020" @default.
- Q99576761 description "scientific article published on 20 September 2020" @default.
- Q99576761 description "wetenschappelijk artikel" @default.
- Q99576761 description "наукова стаття, опублікована 20 вересня 2020" @default.
- Q99576761 name "Efficacy and Safety of Tocilizumab for Polyarticular-Course Juvenile Idiopathic Arthritis in the Open-Label 2-Year Extension of a Phase 3 Trial" @default.
- Q99576761 name "Efficacy and Safety of Tocilizumab for Polyarticular-Course Juvenile Idiopathic Arthritis in the Open-Label 2-Year Extension of a Phase 3 Trial" @default.
- Q99576761 type Item @default.
- Q99576761 label "Efficacy and Safety of Tocilizumab for Polyarticular-Course Juvenile Idiopathic Arthritis in the Open-Label 2-Year Extension of a Phase 3 Trial" @default.
- Q99576761 label "Efficacy and Safety of Tocilizumab for Polyarticular-Course Juvenile Idiopathic Arthritis in the Open-Label 2-Year Extension of a Phase 3 Trial" @default.
- Q99576761 prefLabel "Efficacy and Safety of Tocilizumab for Polyarticular-Course Juvenile Idiopathic Arthritis in the Open-Label 2-Year Extension of a Phase 3 Trial" @default.
- Q99576761 prefLabel "Efficacy and Safety of Tocilizumab for Polyarticular-Course Juvenile Idiopathic Arthritis in the Open-Label 2-Year Extension of a Phase 3 Trial" @default.
- Q99576761 P1433 Q99576761-278A492F-1B6F-41EF-BBCF-648D7B0E7C81 @default.
- Q99576761 P1476 Q99576761-749E52A0-928D-4534-82C2-4AEF3C17BFF2 @default.
- Q99576761 P2093 Q99576761-11656568-693C-4B85-889E-21F3A3A89189 @default.
- Q99576761 P2093 Q99576761-161A9973-2B37-4946-B789-EFCCE4596FBE @default.
- Q99576761 P2093 Q99576761-194F996C-8D1F-4892-BD0C-6DDA17106C26 @default.
- Q99576761 P2093 Q99576761-1E184E97-DC6B-4979-93C5-008D033BF1D9 @default.
- Q99576761 P2093 Q99576761-1FE334CD-B249-4852-BD63-AE4308DD0481 @default.
- Q99576761 P2093 Q99576761-2BD333F0-E7F5-41A1-B4E6-9A12919A2571 @default.
- Q99576761 P2093 Q99576761-315160AD-0E33-466C-A78E-833C99B33FE8 @default.
- Q99576761 P2093 Q99576761-3308091B-7D74-4663-9865-3538930E05E8 @default.
- Q99576761 P2093 Q99576761-36CA3545-9310-4BBC-AFA1-7E6503A01E5F @default.
- Q99576761 P2093 Q99576761-40EABD51-8105-4A95-AB8B-6E8014B77027 @default.
- Q99576761 P2093 Q99576761-423BD7BE-CC26-417E-87E1-CFDE5D38FABE @default.
- Q99576761 P2093 Q99576761-44C97568-3F97-48C3-8F3B-849D41D2A069 @default.
- Q99576761 P2093 Q99576761-7BC1D5FA-9018-4B62-AA0F-62B0969A583E @default.
- Q99576761 P2093 Q99576761-8F26FB44-559B-4A93-8643-5B4C6C8E6C55 @default.
- Q99576761 P2093 Q99576761-9E80E722-3448-496E-A587-3144247DE7EC @default.
- Q99576761 P2093 Q99576761-D8A18EF0-B42A-49EF-B89C-DD29339647A6 @default.
- Q99576761 P2093 Q99576761-E1A2D678-E03F-4849-9F0A-BEFC7D4306D1 @default.
- Q99576761 P2093 Q99576761-E24ABE25-48E0-48BF-AC64-F4FCD76BF5B3 @default.
- Q99576761 P2093 Q99576761-EADB5F02-638B-4BEE-B961-F01D4CE9E6C5 @default.
- Q99576761 P31 Q99576761-355DAF08-A7C8-4D85-8C49-1B20AC618D8B @default.
- Q99576761 P356 Q99576761-7719CAB9-C1E4-41A4-AC74-870D905526BF @default.
- Q99576761 P50 Q99576761-0FCEE624-89EB-4792-B55B-FBBB565ACD1A @default.
- Q99576761 P50 Q99576761-2328BFA1-E927-49D6-84BE-58C6BE4E083F @default.
- Q99576761 P50 Q99576761-56C6E1AF-2344-4E5C-9975-8109CF31273A @default.
- Q99576761 P50 Q99576761-75E488F9-28B4-418C-AD57-F58E0FDFC068 @default.
- Q99576761 P577 Q99576761-0C89BFF4-3393-450A-B35A-B60AF7AE4847 @default.
- Q99576761 P698 Q99576761-0CD5CC41-A0D6-4D1F-9633-BA92F9C202D7 @default.
- Q99576761 P921 Q99576761-B7B07926-ED47-48B7-A77D-BCD7651D39AF @default.
- Q99576761 P921 Q99576761-D4702112-0D1B-4AE3-A4F8-0EEBC78AF1B6 @default.
- Q99576761 P932 Q99576761-05468894-391D-4649-AF63-F4E79E0B63E0 @default.
- Q99576761 P356 ART.41528 @default.
- Q99576761 P698 32951358 @default.
- Q99576761 P1433 Q4797636 @default.
- Q99576761 P1476 "Efficacy and Safety of Tocilizumab for Polyarticular-Course Juvenile Idiopathic Arthritis in the Open-Label 2-Year Extension of a Phase 3 Trial" @default.
- Q99576761 P2093 "Alberto Martini" @default.
- Q99576761 P2093 "Carolina Duarte" @default.
- Q99576761 P2093 "Chantal Job-Deslandre" @default.
- Q99576761 P2093 "Chris Wells" @default.
- Q99576761 P2093 "Earl D Silverman" @default.
- Q99576761 P2093 "Fabrizio De Benedetti" @default.
- Q99576761 P2093 "Graciela Espada" @default.
- Q99576761 P2093 "Inmaculada Calvo Penades" @default.
- Q99576761 P2093 "Kamal N Bharucha" @default.
- Q99576761 P2093 "Manuel Ferrandiz Zavaler" @default.
- Q99576761 P2093 "Paediatric Rheumatology International Trials Organisation (PRINTO), the Pediatric Rheumatology Collaborative Study Group (PRCSG)" @default.
- Q99576761 P2093 "Ricardo M Xavier" @default.
- Q99576761 P2093 "Rik Joos" @default.
- Q99576761 P2093 "Ruben Burgos-Vargas" @default.
- Q99576761 P2093 "Rubén Cuttica" @default.
- Q99576761 P2093 "Sunethra Wimalasundera" @default.
- Q99576761 P2093 "Vladimir Keltsev" @default.
- Q99576761 P2093 "Wendy Douglass" @default.
- Q99576761 P2093 "Zbigniew Zuber" @default.
- Q99576761 P31 Q13442814 @default.
- Q99576761 P356 "10.1002/ART.41528" @default.
- Q99576761 P50 Q57685293 @default.
- Q99576761 P50 Q64689308 @default.
- Q99576761 P50 Q89572697 @default.
- Q99576761 P50 Q91633712 @default.
- Q99576761 P577 "2020-09-20T00:00:00Z" @default.
- Q99576761 P698 "32951358" @default.
- Q99576761 P921 Q425154 @default.
- Q99576761 P921 Q861224 @default.
- Q99576761 P932 "7986602" @default.